XNAS · Healthcare · Biotechnology
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -1.10 | -1.02 | +7.27% | $5.5M | ✅ Beat | +6.53% | -8.45% | — |
| 2026-05-11 | Q1 2026 | -1.08 | -1.32 | -22.22% | $1.9M | ❌ Miss | -5.00% | -30.93% | -34.13% |
| 2026-03-24 |
| Q4 2025 |
| -0.91 |
| -1.16 |
| -27.47% |
| $1.6M |
| ❌ Miss |
| +2.55% |
| +1.33% |
| +1.33% |
| 2025-11-05 | Q3 2025 | -0.68 | -0.59 | +13.24% | $12.5M | ✅ Beat | — | — | — |
| 2025-07-30 | Q2 2025 | -0.67 | -0.53 | +20.90% | $5.0M | ✅ Beat | +6.25% | -1.92% | +25.59% |
| 2025-03-19 | Q4 2024 | -0.40 | -0.46 | -15.00% | $0 | ❌ Miss | +3.06% | +2.23% | -5.53% |
| 2024-08-14 | Q2 2024 | — | -0.40 | — | $0 | — | -3.83% | -4.38% | -6.98% |
| 2024-05-08 | Q1 2024 | -0.84 | -3.53 | -320.24% | $0 | ❌ Miss | -4.82% | -2.10% | -3.71% |
Showing last 8 quarters.